Overview: Anti-CASPR2 TestIntroduction: The Anti-CASPR2 Test looks for antibodies attacking nerve cells, helping diagnose autoimmune encephalitis or neuromyotonia, which can cause seizures, memory issues, or muscle stiffness. Affecting 1 in 100,000 people annually, these conditions pose diagnostic challenges due to their overlap with epilepsy or peripheral nerve disorders, particularly in middle-aged adults. Following 2023 National Institute of Neurological Disorders and Stroke (NINDS) guidelines, it uses immunofluorescence for high specificity, supporting immunology screening. This test is critical for diagnosis, treatment planning, and improving outcomes in neurology, especially in acute settings where early immunotherapy can halt progression.
Other Names: Anti-CASPR2 Antibody Test, CASPR2 Encephalitis Assay.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic reliability.
Historical Milestone: Antibody testing for CASPR2 began in the 2000s with research by Angela Vincent, who linked these antibodies to neuromyotonia and encephalitis. Immunofluorescence advancements in the 2010s by companies like Euroimmun improved detection, surpassing earlier radioimmunoassay methods that lacked sensitivity for low-titer antibodies.
Purpose: Detects anti-CASPR2 antibodies to diagnose autoimmune encephalitis or neuromyotonia, guides immunotherapy with steroids or IVIG, and evaluates patients with seizures, memory issues, or muscle stiffness, aiming to reduce nerve inflammation and prevent long-term neurological deficits.
Test Parameters: Anti-CASPR2 antibody levels
Pretest Condition: No special preparation required to reflect natural antibody levels. Collect serum or cerebrospinal fluid (CSF). Report history of seizures, muscle stiffness, or recent infections.
Specimen: Serum (SST, 2-5 mL), CSF (sterile container, 1-2 mL); 2 mL serum in SST or 1 mL CSF in sterile container. Transport in a biohazard container to prevent degradation.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document seizures, muscle stiffness, or recent infections. Include current medications, cancer history, or family history of autoimmune diseases, noting any recent neurological changes.
Consent: Written consent required, detailing the test's purpose, encephalitis risks (e.g., coma, memory loss), and potential risks of sample collection, with emphasis on prompt treatment and neurological monitoring.
Procedural Considerations: Uses immunofluorescence to detect anti-CASPR2 antibodies, requiring laboratories with fluorescent microscopes and trained immunologists. Results are available in 3-5 days, supporting acute care. Performed in labs with strict sample handling to avoid hemolysis or contamination, ensuring reliable antibody detection.
Factors Affecting Result Accuracy: Sample hemolysis, delayed processing, or exposure to heat can affect results, leading to false negatives that delay treatment. Medications or concurrent infections may alter antibody levels, requiring clinical correlation and repeat testing if needed.
Clinical Significance: Positive anti-CASPR2 confirms autoimmune encephalitis or neuromyotonia, guiding steroids or plasma exchange to reduce symptoms. A patient with early treatment might avoid permanent disability, while untreated cases can lead to death or severe neurological damage. Normal levels may require MRI or additional antibody tests to rule out other causes.
Specialist Consultation: Consult a neurologist or immunologist for result interpretation and management, particularly for patients with cancer history, where oncological and neurological care is critical.
Additional Supporting Tests: Brain MRI, EMG, or anti-LGI1 antibody test to confirm diagnosis and assess nerve function, aiding in comprehensive care and monitoring treatment response.
Test Limitations: Non-specific for disease subtype; clinical correlation with imaging and symptoms is needed. Sensitivity varies with disease stage, and false negatives may occur in early phases, requiring follow-up testing.
References: NINDS Guidelines, 2023; Journal of Neurology, Vincent A, 2022.
